AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00439803 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 doses of placebo given at T=0, 8, 24 weeks via the IM route
Study NCT00439803 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVX601
Description: 3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the SC route
Study NCT00439803 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 doses of placebo given at T=0, 8, 24 weeks via the SC route
Study NCT00439803 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVX601
Description: 3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the IM route
Study NCT00439803 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AVX601
Description: 3 doses of placebo given at T=0, 8, 24 weeks via the IM route
Study NCT00439803 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVX601
Description: 3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the SC route
Study NCT03459443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Danicopan was to be administered as an oral tablet.
Study NCT02619981 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restorative procedure
Description: A restorative dental procedure requiring maxillary buccal infiltration anesthesia, and not exceeding 30 minutes of working time
Study NCT02455791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-Guided Biopsy
Description: Ultrasound-guided biopsy of tumor site. A needle is inserted into the affected area using an ultrasound to collect cells or tissue from a tumor mass. Two (2) types of samples collected.
Study NCT01429675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bonviva
Description: 150mg Ibandronate once a month
Study NCT01429675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bonviva
Description: 150mg Ibandronate once a month
Study NCT03288675 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: aiTBS
Description: In the active aiTBS arm, the patients will receive 100 cycli of thetaburst trains of 2s, separated by an inter-train-interval of 6 seconds, delivered on the left dorsolateral prefrontal cortex (DLPFC; i.e. 3000 pulses per session). On each stimulation day, a given patient will receive 5 sessions with a between-session interval of 15 minutes. The treatment protocol of in total 20 aiTBS sessions will be spread over 4 days (i.e. 60.000 pulses in total). The sham coil has been specifically developed to mimic the real one.
Study NCT03288675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aiTBS
Description: In the active aiTBS arm, the patients will receive 100 cycli of thetaburst trains of 2s, separated by an inter-train-interval of 6 seconds, delivered on the left dorsolateral prefrontal cortex (DLPFC; i.e. 3000 pulses per session). On each stimulation day, a given patient will receive 5 sessions with a between-session interval of 15 minutes. The treatment protocol of in total 20 aiTBS sessions will be spread over 4 days (i.e. 60.000 pulses in total). The sham coil has been specifically developed to mimic the real one.
Study NCT03288675 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CCT
Description: By training working memory processing, the CCT aims at modulating similar prefrontal cortex regions as being stimulated previously by aiTBS, namely the DLPFC. thereby possibly stabilizing clinical effects of aiTBS over time. In total 20 sessions of CCT vs. control training (of approximately 25 minutes per session), will be spread over a period of 4 weeks.
Study NCT03288675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CCT
Description: By training working memory processing, the CCT aims at modulating similar prefrontal cortex regions as being stimulated previously by aiTBS, namely the DLPFC. thereby possibly stabilizing clinical effects of aiTBS over time. In total 20 sessions of CCT vs. control training (of approximately 25 minutes per session), will be spread over a period of 4 weeks.
Study NCT03288675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRI
Description: All patients will be prescribed antidepressant medication (SSRI) again when starting the CCT (vs. control training).
Study NCT03288675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI
Description: All patients will be prescribed antidepressant medication (SSRI) again when starting the CCT (vs. control training).
Study NCT04151212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT5906 injection
Description: Signal dose escalation starting from 0.3mg. Route of administration: intravitreal injection
Study NCT03186209 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab subcutaneously on study week 0 until study week 40 inclusive.
Study NCT03186209 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneously on study week 0 until study week 40 inclusive.
Study NCT03889184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitating meals-on-wheels service
Description: the meals-on-wheels service will be specifically targeted for old people discharged from hospital, receiving exercise rehabilitation in the municipality or already receiving meals-on-wheels
Study NCT00971659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine + exenatide + preexisting metformin
Description: insulin glargine once daily subcutaneously over 4 weeks, dose adjustment according to a treat-to-target algorithm, exenatide 5ug twice daily subcutaneously for 2 weeks, then 10ug twice daily for 2 weeks, continuation of preexisting metformin
Study NCT00971659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine + sitagliptin + preexisting metformin
Description: insulin glargine once daily subcutaneously over 4 weeks, dose adjustment according to a treat-to-target algorithm, sitagliptin 100 mg once daily in the morning over 4 weeks, continuation of preexisting metformin
Study NCT00971659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine + preexisting metformin
Description: insulin glargine once daily subcutaneously over 4 weeks, continuation of preexisting metformin
Study NCT04205240 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic hematopoietic stem cell transplantation
Study NCT04205240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04205240 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV
Study NCT04205240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT04205240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT04205240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO
Study NCT04205240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given PO or IV
Study NCT01810471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Applying ankle support device (white non-elastic tape, kinesiotape (TM), soft brace (Malleotrain TM)
Study NCT03314103 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: One shot of the varicella-zoster virus vaccine
Description: One shot of the live attenuated varicella-zoster virus vaccine (with live virus >=4.3 LgPFU per dose)
Study NCT03314103 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: one shot of placebo
Description: one shot of placebo with no live virus
Study NCT01660971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study NCT01660971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO
Study NCT01660971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT04268641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 1
Description: Materials used for the course :~1. : Standard Wheelchair~2. : Standard Wheelchair + Seat back + Positioning cushion~3. : Standard Wheelchair + Seat back + Positioning cushion + Belt
Study NCT04268641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 2
Description: Materials used for the course :~1. : Standard Wheelchair~2. : Standard Wheelchair + Seat back + Positioning cushion + Belt~3. : Standard Wheelchair + Seat back + Positioning cushion
Study NCT04268641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 3
Description: Materials used for the course :~1. : Standard Wheelchair + Seat back + Positioning cushion~2. : Standard Wheelchair + Seat back + Positioning cushion + Belt~3. : Standard Wheelchair
Study NCT04268641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 4
Description: Materials used for the course :~1. : Standard Wheelchair + Seat back + Positioning cushion~2. : Standard Wheelchair~3. : Standard Wheelchair + Seat back + Positioning cushion + Belt
Study NCT04268641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 5
Description: Materials used for the course :~1. : Standard Wheelchair + Seat back + Positioning cushion + Belt~2. : Standard Wheelchair~3. : Standard Wheelchair + Seat back + Positioning cushion
Study NCT04268641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 6
Description: Materials used for the course :~1. : Standard Wheelchair + Seat back + Positioning cushion + Belt~2. : Standard Wheelchair + Seat back + Positioning cushion~3. : Standard Wheelchair
Study NCT02366494 — intervention group
Intervention type: DRUG
Intervention: Bicalutamide
Description: ANDROGEN BLOCKADE
Study NCT02366494 — intervention group
Intervention type: DRUG
Intervention: Leuprolide
Description: ANDROGEN BLOCKADE
Study NCT02366494 — intervention group
Intervention type: DRUG
Intervention: Goserelin
Description: ANDROGEN BLOCKADE
Study NCT02366494 — intervention group
Intervention type: DRUG
Intervention: Triptorelin
Description: ANDROGEN BLOCKADE
Study NCT02366494 — intervention group
Intervention type: DRUG
Intervention: Docetaxel
Description: Chemo hormonal therapy
Study NCT02366494 — intervention group
Intervention type: DRUG
Intervention: Abiraterone
Description: Chemo hormonal therapy
Study NCT02366494 — intervention group
Intervention type: DRUG
Intervention: Apalutamide
Description: Nonsteroidal antiandrogen medication
Study NCT02366494 — intervention group
Intervention type: DRUG
Intervention: Enzalutamide
Description: Nonsteroidal antiandrogen medication
Study NCT04390880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: Study participants will receive intravenous administration of 18F-DCFPyL and undergo a PET/CT imaging study. Patients may be reenrolled in the study, if 18F-DCFPyL PET/CT is performed for subsequent management decision.
Study NCT03796559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magseed Marker
Description: Implantable Magseed marker for marking lesions in soft tissue, detected using the Sentimag handheld probe.
Study NCT04165070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT04165070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion
Study NCT04165070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion
Study NCT04165070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion
Study NCT04165070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vibostolimab
Description: IV infusion
Study NCT04165070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boserolimab
Description: IV infusion
Study NCT04165070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4830
Description: IV infusion
Study NCT04165070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-0482
Description: IV Infusion
Study NCT04165070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ifinatamab Deruxtecan (I-DXd)
Description: IV infusion
Study NCT04165070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER3-DXd
Description: IV Infusion
Study NCT01346358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-CS4
Study NCT02511665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Given metformin
Study NCT02511665 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET-MRI Scan
Description: Patients will under go 2 PET-MRI scans in the PET-MRI substudy arm one before treatment with metformin and one after
Study NCT02511665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given placebo
Study NCT03484130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Sodium loaded diet
Description: At baseline, and annually, participants will undergo aldosterone dynamic testing after \~5 days of a sodium loaded diet. The diet will consist of >180 mmol/day of sodium, \~50 mmol/day of potassium, and 600mg/d of calcium.
Study NCT03484130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Restricted sodium diet
Description: At baseline, and annually, participants will undergo aldosterone dynamic testing after \~5 days of a sodium restricted diet. The diet will consist of \<40 mmol/day of sodium, \~50 mmol/day of potassium, and 600mg/d of calcium.
Study NCT02619981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary infiltration anesthesia with 2%Lidocaine
Description: 1.8ml of 2% Lidocaine with adrenaline administered using a 27 gauge 21mm needle
Study NCT04405791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active stimulation group Sham stimluation group
Description: Participants are randomly assigned to either treatment group or sham group for application of transcranial low intensity focused ultrasound stimulation. For sham group, transducer is surrounded by rubber band in order to block the transmission of ultrasonic wave.~Before initiating transcranial low intensity focused ultrasonic stimulation, in order to identify anatomical structure of the brain, Brain Magnetic Resonance Image(MRI) and Computer Tomography(CT) will be taken. For image coordination, multi-modal stick(fiducial marker, PinPoint) will be attached to the participant.~With acquired brain images of the participant, researchers identify participant's dorsolateral prefrontal cortex(DLPFC) region, and design focused ultrasound focus targeting, image-guidance method.~The treatment is started by targeting left DLPFC region according to assigned groups. Both the treatment and sham group will be under procedure for 2 weeks, 3 times a week.
Study NCT04405791 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Active stimulation group Sham stimluation group
Description: Participants are randomly assigned to either treatment group or sham group for application of transcranial low intensity focused ultrasound stimulation. For sham group, transducer is surrounded by rubber band in order to block the transmission of ultrasonic wave.~Before initiating transcranial low intensity focused ultrasonic stimulation, in order to identify anatomical structure of the brain, Brain Magnetic Resonance Image(MRI) and Computer Tomography(CT) will be taken. For image coordination, multi-modal stick(fiducial marker, PinPoint) will be attached to the participant.~With acquired brain images of the participant, researchers identify participant's dorsolateral prefrontal cortex(DLPFC) region, and design focused ultrasound focus targeting, image-guidance method.~The treatment is started by targeting left DLPFC region according to assigned groups. Both the treatment and sham group will be under procedure for 2 weeks, 3 times a week.
Study NCT00688896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-705 600 mg and pravastatin 40 mg
Description: * JTT-705 300 mg tablets, 600 mg dose, 2 tablets, oral, once daily, immediately following breakfast and/or assessment~* Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime
Study NCT00688896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-705 300 mg and pravastatin 40 mg
Description: * JTT-705 300 mg tablets, 300 mg dose, 1 tablet, oral, once daily, immediately following breakfast and/or assessment~* Placebo tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments~* Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime
Study NCT00688896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and pravastatin 40 mg
Description: * Placebo tablets, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~* Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime
Study NCT03253796 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Injections of 50 mg golimumab. At the investigator's discretion, participants with a body weight of more than 100 kg could receive 100 mg injections with golimumab.
Study NCT03253796 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Golimumab
Description: Injections of 50 mg golimumab. At the investigator's discretion, participants with a body weight of more than 100 kg could receive 100 mg injections with golimumab.
Study NCT03253796 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injections of matching placebo for golimumab.
Study NCT03253796 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injections of matching placebo for golimumab.
Study NCT02516696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: 500mg PO twice daily on days 1-28 for a 28-day cycle.
Study NCT02516696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle
Study NCT02516696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: 25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle
Study NCT02516696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger.
Study NCT02516696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger.
Study NCT04094597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin
Description: lactoferrin is given orally in comparsion to placebp
Study NCT04094597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebp is given in 2 ml saline
Study NCT03651700 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active TMS
Description: Active TMS will be at 90% motor threshold
Study NCT00986973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapropterin
Description: All subjects will receive 20 mg/kg/day Sapropterin (KUVAN) for four months. Subjects will be examined with fluorodeoxyglucose positron emission tomography (FDG-PET) brain imaging, physical and neurological exam, blood tests for phenylalanine (Phe) and tyrosine levels, and neuropsychological testing before and 4 months after KUVAN therapy. Subjects Phe and tyrosine levels will be monitored weekly during the study and subjects will keep 3-day diet records to allow for calculation of Phe intake.
Study NCT03651700 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS
Description: Sham TMS will be administered
Study NCT03651700 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CILT
Description: 60-90 minutes of CILT will be administered during each treatment session
Study NCT03651700 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: CILT
Description: 60-90 minutes of CILT will be administered during each treatment session
Study NCT01861808 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lumbar puncture
Description: The only intervention is the lumbar puncture on the patients to obtain a Cerebrospinal Fluid sample
Study NCT04643808 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous auricular vagus nerve stimulation
Description: Microcurrent stimulation delivered to the left tragus, with stimulation 'on' during sucking from a bottle, and 'off' at rest during bottle feeding
Study NCT01593826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Charcoal and Budesonide/formoterol Easyhaler 320/9 microg
Description: 2 inhalations as a single dose
Study NCT01593826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Charcoal and Symbicort Turbuhaler
Description: 2 inhalations as a single dose
Study NCT01593826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol Easyhaler 320/9 microg
Description: 2 inhalations as a single dose
Study NCT01593826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort Turbuhaler forte
Description: 2 inhalations as a single dose
Study NCT02014324 — intervention group
Intervention type: PROCEDURE
Intervention: Endosonography
Description: Complete endosonographic mediastinal staging is performed in 2 steps:~1. Systematic EBUS (airways)~2. Systematic EUS-B (esophagus)